Skip to search formSkip to main contentSkip to account menu

CCI 779

Known as: Rapamycin Analog CCI-779, Cell Cycle Inhibitor 779, CCI-779 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
BackgroundLiver cancer is one of the most frequent cancers in the world. Targeted therapy of cancer with specific inhibitors is… 
2007
2007
Background: This study set out to investigate the antitumor effects of a treatment strategy combining the mTOR inhibitor CCI-779… 
2006
2006
The PI3K/AKT/mTOR pathway is frequently activated in a variety of cancers giving hope that that this pathway may prove to be a… 
2006
2006
7573 Background: Mantle cell lymphoma (MCL) is a distinct type of B-cell lymphoma associated with transient response to… 
Review
2005
Review
2005
1505 Background: CCI-779 is a small molecule inhibitor of the mammalian target of rapamycin (mTOR), and represents a rational… 
2004
2004
Temsirolimus (CCI-779, Wyeth Pharmaceuticals) has been shown to inhibit proliferation of a variety of tumors and induce G1 cell… 
2004
2004
7523 Background: CCI-779 mTOR kinase inhibitor is a targeted chemotherapeutic agent that inhibits malignant cell cycle… 
2004
2004
1503 Background: CCI-779 is a small molecule inhibitor of the mammalian target of rapamycin (mTOR). mTOR is a rational…